Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
The Oncologist|June 21, 2024
Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancersBushra Shariff, Reagan M Barnett, Farshid Dayyani, et al.
Surgery|October 10, 2018
Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trialFadi S Dahdaleh, Scott K Sherman, Elizabeth C Poli, et al.
Journal of the American College of Surgeons|July 15, 2022
Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time?Masaya Nakauchi, Colin M Court, Laura H Tang, et al.
Annals of Surgery|July 13, 2022
A Novel Microbiome Signature in Gastric Cancer: A Two Independent Cohort Retrospective AnalysisMiseker Abate, Elvira Vos, Mithat Gonen, et al.
Journal of Gastrointestinal Oncology|July 12, 2023
Perioperative versus total neoadjuvant chemotherapy in gastric cancerJessica Yang, Megan Greally, Vivian E Strong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot StudyMelissa A Lumish, Steven B Maron, Viktoriya Paroder, et al.
Annals of Surgical Oncology|February 10, 2021
Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of RecurrenceMasaya Nakauchi, Elvira Vos, Laura H Tang, et al.
Annals of Surgical Oncology|April 8, 2021
Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer ResectionMasaya Nakauchi, Elvira L Vos, Laura H Tang, et al.
The Oncologist|June 29, 2019
FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic LandscapeSamuel J Klempner, Russell Madison, Vivek Pujara, et al.
Annals of Surgery|November 20, 2020
Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?Smita Sihag, Tamar Nobel, Meier Hsu, et al.
Pageof 6